[Caution] stacking with a sulfonylurea is a real hypo risk, not a theoretical one
stacking with a sulfonylurea is a real hypo risk, not a theoretical one, which sounds obvious until you try to state the evidence for it.
Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.
Panicked over a first-day sensor reading and rebuilt my week around it. It was the sensor.
Time in range told me far more than the average did. Two quarters with the same A1c looked completely different on the sensor.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.
Yes — the person managing your diabetes is the one to talk to, and this board is explicit about that.
metformin and an incretin agonist are not in competition
What does time in range look like, not just the average?
A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.
dose for glycaemic control is not the same conversation as dose for weight
Retitled — the original quoted an obesity endpoint as a glycaemic one.
Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.
a1c can be affected by things that have nothing to do with glucose
Push back: one sensor reading is not a data point worth acting on, especially in the first day of wear.
My fasting insulin moved and it turned out to have nothing to do with glucose at all.
Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.
Continuous monitoring shows the shape: postprandial excursions, overnight behaviour and time in range. Two people with identical A1c can have very different distributions.
Brought the whole CGM export to my appointment rather than one number. Entirely different conversation.
the diabetes trials report different endpoints from the obesity ones
That is a sensor value, not a plasma value, and the two are not interchangeable at that level of precision.
Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.
Cosigning that postprandial excursions improve first and the fasting number is the laggard.
On hypoglycaemia, because the risk gets attributed to the wrong thing constantly.
Incretin-based agents stimulate insulin secretion in a glucose-dependent way: the effect scales with glycaemia rather than acting unconditionally. That is why monotherapy risk is low. Where risk rises substantially is in combination with agents that lower glucose independently of the current level.
Which means the question "does this cause hypos" is not answerable without knowing the rest of the regimen — and that the person who can answer it is the one who wrote the regimen. Nothing on this board is a substitute for that conversation, and the good threads here end by saying so.
The order things move in, since nobody explains it and it worries people.
Postprandial excursions generally respond earliest. Variability tends to narrow before the average does, which is visible on a sensor and invisible on a lab result. Fasting glucose is often the laggard, and A1c — being a three-month average — is the last thing to reflect anything.
So a month in which the sensor looks better and the fasting number has not moved is the ordinary sequence, not a contradiction. Knowing that in advance would have saved me a quarter of unnecessary worry, which is why it is worth writing down.